A phase 2b randomized trial of the GLP-1/glucagon dual agonist cotadutide in type 2 diabetes and CKD, with dose-dependent reductions in albuminuria at week 14. PICO summary and expert commentary.
Browsing: Diabetes Complications
Microvascular and macrovascular complications of diabetes: retinopathy, nephropathy, neuropathy, and cardiovascular risk.
A post hoc analysis of the SUSTAIN 6 trial reports that once-weekly semaglutide was associated with lower odds of developing diabetic kidney disease in adults with type 2 diabetes who had no kidney disease at baseline. PICO summary and expert commentary.
A 32-week post hoc MRI substudy of 80 patients with type 2 diabetes finds semaglutide and empagliflozin each reduce cortical ADC and total kidney volume, with combination therapy lowering kidney volume most. PICO summary and expert commentary.
In the FLOW randomised controlled trial, weekly semaglutide reduced major kidney disease events and cardiovascular death in patients with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
A phase 2b trial of the GLP-1/glucagon receptor agonist cotadutide showed dose-dependent reductions in albuminuria in type 2 diabetes with CKD. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN 6 suggesting once-weekly semaglutide lowered new-onset diabetic kidney disease in type 2 diabetes. PICO summary and expert commentary.
Prespecified FLOW subgroup analysis testing whether semaglutide’s kidney and cardiovascular benefits hold with or without baseline SGLT2 inhibitor use. PICO summary and expert commentary.